Cover Image
市場調查報告書

美國的再生醫療市場 (2016-2020年)

Regenerative Medicine Market in the US 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 277867
出版日期 內容資訊 英文 77 Pages
訂單完成後即時交付
價格
Back to Top
美國的再生醫療市場 (2016-2020年) Regenerative Medicine Market in the US 2016-2020
出版日期: 2015年12月23日 內容資訊: 英文 77 Pages
簡介

再生醫療是為了治療人的細胞、組織,以及內臟器官,誘導治療用,或涉及利用在研究室培養的人體組織的流程。那是作為治療疾病和傷口的媒體,代替無正常作用或損傷的細胞,幫助產生新細胞的新治療領域。多樣疾病治療的利用受到預期,美國的再生醫療市場,在2016-2020年期間預計以超越33%的驚異性年複合成長率 (CAGR) 成長。

本報告以美國的再生醫療市場為主題,提供基因治療及市場概要、開發中產品狀況、法規情形、市場發展推動因素、市場上的課題與其影響、各產品/各用途的市場現況與展望相關調查分析、主要的供應商簡介彙整。

第1章 摘要整理

第2章 調查範圍

  • 市場概要
  • 主要供應商的產品提供

第3章 市場調查手法

  • 調查手法
  • 經濟指標

第4章 簡介

  • 市場的主要特徵

第5章 基因治療:再生醫療的新領域

第6章 產品研發線

第7章 法規方案

  • FDA (美食品藥物管理局) 的認證次序

第8章 市場形勢

  • 市場概要
  • 市場規模、預測
  • 波特的五力分析

第9章 市場區隔,各產品

  • 細胞治療
  • 美國的細胞治療市場
  • 支架
  • 美國的支架市場

第10章 市場區隔,各用途

  • 皮膚科學
  • 肌肉骨骼系統
  • 眼球
  • 心血管

第11章 市場發展推動因素

  • 慢性疾病盛行率的上升
  • 技術創新
  • 研究開發活動的投資增加

第12章 推動因素的影響

第13章 市場課題

  • 嚴格法規認證次序
  • 倫理的課題
  • 臨床資料的不足

第14章 推動因素與課題的影響

第15章 市場趨勢

  • 開發中產品的增加
  • 策略性聯盟
  • 再生醫療降低醫療成本的可能性

第16章 業者情勢

  • 競爭模式
  • 主要消息
  • 合併、收購
  • 主要供應商分析,2015年
  • 其他主要供應商

第17章 主要供應商分析

  • Acelity
  • Mesoblast
  • Organogenesis
  • Reprocell
  • Stryker

第18章 附錄

  • 簡稱集

第19章 關於Technavio

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR7731

Market outlook of the regenerative medicine market in the US

Regenerative medicine deals with the process of using therapeutically-induced or laboratory grown human tissue to treat diseased or injured human cells, tissues, or organs. It is an emerging field of treatment that helps in producing new cells to substitute malfunctioning or injured cells as a vehicle to treat disease and injury. The regenerative medicine market can be characterized into three major modalities, namely tissue engineering, biomaterials/biomolecules, and stem cell therapy.

Technavio's market research analysts expect the regenerative medicine market in the US to grow at a fast pace, posting a remarkable CAGR of more than 33% during the forecast period because of the growing demand for tissue-engineered and stem cell products for the treatment of various diseases. The potential of these medicines in regenerating diseased organs is one of the major factors that drives the market in the US. The stem cells application and advancements in nanotechnology will further drive the progress in this market.

Segmentation by product and analysis of - cell therapy and scaffold

Cell therapy helps in treating the diseases or to improving the functioning of the existing cells, by administrating of cells into the body. This therapy addresses medical conditions related to the bone, cartilage, heart, skin, digestive system, reproductive system, eye, blood, spine, brain, and the nervous system. In 2015, cell therapy segment accounted for approximately 80% of the market share.

The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -

  • Cell therapy
  • Scaffold

Segmentation by application and analysis of - dermatology, musculoskeletal, ocular, and cardiovascular

The year 2015 saw the precedence of the dermatology segment, accounting for a market share of more than 51%. Dermatology includes the treatment of burns and chronic wounds that requires a quick response, and skin grafting is essential in many cases. Factors such as the increase in obesity and diabetes, growing elderly population, and an increase in life expectancy are some of the causes contributing to the growth of the dermatology market.

The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -

  • Dermatology
  • Musculoskeletal
  • Ocular
  • Cardiovascular

Competitive landscape and key vendors - AkzoNobel, Jotun, PPG

Regenerative medicine market in the US is highly competitive and fragmented because of the presence of several established vendors and this competitive environment is expected to intensify with advances in R&D and technological innovations. International players are likely to acquire regional or local players to enhance their products and expand their market share during the forecast period.

The top vendors in the market are -

  • Acelity
  • Mesoblast
  • Organogenesis
  • Reprocell
  • Stryker

Other prominent vendors include Aastrom Biosciences, Acologix, AlloCure, Allosource, Alphatec Spine, Altrika, Amorcyte, Argos Therapeutics, Athersys, Avita Medical, Axogen, Bacterin International, Baxter, Bellicum Pharmaceuticals, BioCardia, BioLife Solutions, BioRestorative Therapies, BioTissue Technologies, Bluebird Bio, BrainStorm Cell Therapeutics, Calimmune, Capricor, Celyad (Cardio3 BioSciences), Cell Medica, Cesca, CryoLife, Cynata Therapeutics, Cytori, Cytori Therapeutics, Dendreon, DiscGenics, Fate Therapeutics, Fibrocell, Fibrocell Science, Forticell Bioscience, Fortress Biotech, Gamida Cell, Geron, Harvard Apparatus Regenerative Technology, Healthpoint, Histogen, Histogenics, Humacyte, Immunocellular Therapeutics P, Integra Life Sciences, Intercytex, InVivo Therapeutics, iSTO Technologies, Juventas Therapeutics, Kensey Nash, Kiadis Pharma, Kinetic Concept, Living Cell Technologies, MaxCyte, Medtronics, Mesoblast, MiMedix Group, Nanofiber Solutions CTO, Nanotope, Neuralstem, Newlink Genetics, Northwest Biotherapeutics, NovaRx, Ocata Therapeutics, Opexa , Therapeutics, Organovo Holdings, Orteq, Orthofix, Osiris Therapeutics, Osteotech, Pfizer, Pluristem Therapeutics, Prima BioMed, Q Therapeutics, RhinoCyte, RTI Surgical, SanBio, Sangamo, Shire Regenerative Medicine, StemCells, Stratatech, TEI Biosciences, Tengion, Thermo Fischer Scientific, TiGenix, Tissue Genesis, TissueGene, VentriNova, Vericel, ViaCyte, Vistagen, and Zimmer.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2020?
  • What are the key factors driving the regenerative medicine market in the US?
  • What are the key market trends impacting the growth of the regenerative medicine market in the US?
  • What are the challenges to market growth?
  • Who are the key vendors in the regenerative medicine market in the US?
  • What are the market opportunities and threats faced by the vendors in the regenerative medicine market in the US?
  • What are the key outcomes of the five forces analysis of the regenerative medicine market in the US?

Technavio also offers customization on reports based on specific client requirement.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Gene therapy: An emerging field in regenerative medicine

PART 06: Pipeline portfolio

PART 07: Regulatory scenario

  • FDA process

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation by product

  • Cell therapy
  • Cell therapy market in US
  • Scaffold
  • Scaffold market in US

PART 10: Market segmentation by application

  • Dermatology
  • Musculoskeletal
  • Ocular
  • Cardiovascular

PART 11: Market drivers

  • Rise in prevalence of chronic diseases
  • Technological innovations
  • Increase in investment for research and development activities

PART 12: Impact of drivers

PART 13: Market challenges

  • Stringent regulatory approval process
  • Ethical challenges
  • Lack of clinical data

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Increase in pipeline products
  • Strategic alliances
  • Potential of regenerative medicine toward decreasing healthcare costs

PART 16: Vendor landscape

  • Competitive scenario
  • Key news
  • Mergers and acquisitions
  • Key vendor analysis 2015
  • Other prominent vendors

PART 17: Key vendor analysis

  • Acelity
  • Mesoblast
  • Organogenesis
  • Reprocell
  • Stryker

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Number of ongoing clinical trials
  • Exhibit 03: Gene therapy pipeline products based on indication
  • Exhibit 04: Gene therapy research by sponsorship
  • Exhibit 05: Some of the pipeline products of gene therapy
  • Exhibit 06: Pipeline products of regenerative medicine for cardiovascular diseases
  • Exhibit 07: Pipeline products of regenerative medicine for central nervous system diseases
  • Exhibit 08: Pipeline products of regenerative medicine for spine and orthopedics diseases
  • Exhibit 09: Pipeline products of regenerative medicine for diabetes and autoimmune diseases
  • Exhibit 10: Overview of number of companies and products of regenerative medicine
  • Exhibit 11: Financial performance of regenerative medicine 2013 and 2014
  • Exhibit 12: Marketed products of different therapy areas in 2014
  • Exhibit 13: Regenerative medicine stakeholders
  • Exhibit 14: Guidelines to be followed prior to the initiation of clinical studies for regenerative products
  • Exhibit 15: Regenerative medicine market in US 2015-2020 ($ millions)
  • Exhibit 16: Five forces analysis
  • Exhibit 17: Cell therapy procedure
  • Exhibit 18: Cell therapy market in US 2015-2020 ($ millions)
  • Exhibit 19: Scaffold market in US 2015-2020 ($ millions)
  • Exhibit 20: Segmentation of regenerative medicine market in US 2015-2020 ($ millions)
  • Exhibit 21: Segmentation of regenerative medicine market in US 2015-2020
  • Exhibit 22: Segmentation of regenerative medicine by application 2015
  • Exhibit 23: Revenues funded by federal agencies for regenerative medicine research
  • Exhibit 24: Impact of drivers
  • Exhibit 25: Impact of drivers and challenges
  • Exhibit 26: Some of the mid- and late-stage pipeline products for regenerative medicine
  • Exhibit 27: Mesoblast: Key takeaways
  • Exhibit 28: Reprocell: Key takeaways
  • Exhibit 29: Acelity: Key takeaways
  • Exhibit 30: Organogenesis: Key takeaways
  • Exhibit 31: Stryker: Key takeaways
  • Exhibit 32: Acelity: Business segmentation by revenue 2014
  • Exhibit 33: Acelity: Business segmentation by revenue 2013 and 2014
  • Exhibit 34: Acelity: Geographical segmentation by revenue 2014
  • Exhibit 35: Mesoblast: Product pipeline
  • Exhibit 36: Organogenesis: Product offerings
  • Exhibit 37: Reprocell: Product categories
  • Exhibit 38: Stryker: Business/product segmentation by revenue 2014
  • Exhibit 39: Stryker: Business segmentation by revenue 2013 and 2014 ($ millions)
Back to Top